Prosecution Insights
Last updated: October 04, 2026

Revelation Biosciences Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Revelation Biosciences Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, LUCY MINYU TIEN, in 1 distinct art unit. LUCY MINYU TIEN is the busiest examiner, holding 1 busiest examiner pending action. With 1 pending office action, the company's current prosecution is focused on this single matter.

Because there is only 1 pending office action, the entire current strategy for the Biotechnology & Pharmaceuticals area rests with LUCY MINYU TIEN. This 1 distinct examiner and 1 distinct art unit combination means that the applicant does not have to navigate multiple examination styles or conflicting art unit policies. Practitioners should focus on the specific prosecution history of LUCY MINYU TIEN, as this busiest examiner handles the only busiest examiner pending action in the portfolio. The 1:1 ratio between the pending office action and the distinct examiner ensures that all current efforts are directed toward a single point of contact within the patent office.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
TIEN, LUCY MINYU 1 59.3% +39.2%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18562719 MPLA COMPOSITIONS AND METHODS OF USE TIEN, LUCY MINYU 17d overdue

Top Art Units

Art UnitApps
1612 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18562719 MPLA COMPOSITIONS AND METHODS OF USE TIEN, LUCY MINYU 1612 §103DP Final Rejection 17d overdue Pending Nov 20, 2023

Managing Revelation Biosciences Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month